Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
- 35 Downloads
The role of acetylator phenotype in determining the response to hydralazine when it was added to diuretic and β-blocker at doses not exceeding 200 mg daily was examined in 57 hypertensive patients. 81% of rapid acetylators needed 200 mg hydralazine daily compared to 38% of slow acetylators (p<0.01). Despite higher doses of hydralazine the blood pressure was controlled in only 27% of rapid acetylators compared to 65% of slow acetylators (p<0.02). The relation of acetylator phenotype to blood pressure response was statistically independent of initial blood pressure, age, sex, body weight and serum creatinine (p<0.005). Current recommendations on hydralazine dosage are unsatisfactory for the 40% of hypertensive patients who are rapid acetylators. We suggest measurement of the acetylator phenotype in patients who respond incompletely to 200 mg hydralazine daily. About 70% of these patients will be rapid acetylators in whom the dose of hydralazine can be increased safely.
Key wordsacetylator phenotype hydralazine response hypertension blood pressure control lupus syndrome
Unable to display preview. Download preview PDF.
- 1.Ramsay LE (1980) Diuretic and β-blocker in hypertension — then what? J R Coll Physicians Lond 14: 249–253Google Scholar
- 2.Ludden TM, McNay JL, Shepherd AMM, Lin MS (1982) Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet 7: 185–205Google Scholar
- 3.Zacest R, Koch-Weser J (1972) Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther 13: 420–425Google Scholar
- 4.Silas JH, Ramsay LE, Freestone S (1982) Hydralazine once daily in hypertension. Br Med J 284: 1602–1604Google Scholar
- 5.Hunyor SN (1975) Hydralazine and β-blocker in refractory hypertension with characterization of acetylator phenotype. Aust NZ J Med 5: 530–536Google Scholar
- 6.Vandenburg MJ, Wright P, Holmes J, Rogers HJ, Ahmad RA (1982) The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype. Br J Clin Pharmacol 1982; 13: 747–750Google Scholar
- 7.Kalowski S, Hua ASP, Whitworth JA, Kincaid-Smith P (1979) Hydralazine with beta-blockade and diuretic in the treatment of hypertension. Med J Aust 12: 439–440Google Scholar
- 8.Bing RF, Russel GI, Thurston H, Swales JD (1980) Hydralazine in hypertension: is there a safe dose? Br Med J 281: 353–4Google Scholar
- 9.Winchester JF, Ward DM, McKillop JH, Kennedy AC (1976) Hydralazine or phentolamine as adjuncts to beta-adrenoceptor blockade/thiazide therapy in hypertension. Br J Clin Pharmacol 3: 863–7Google Scholar
- 10.Wilcox RG, Mitchell JRA (1977) Contribution of atenolol, bendrofluazide and hydralazine to management of severe hypertension. Br Med J 2: 547–50Google Scholar
- 11.Vree TB, Hebster YA, Baars AM, Damsona JE, van Derkleijh E (1978) Determination of trimethoprim and sulphamethazole (co-trimoxazole) in body fluids by means of high performance liquid chromatography. J Chromatogr 146: 103–12Google Scholar
- 12.Baker, RJ, Nelder JA (1978) The GLIM system. Generalised Linear Interactive Modelling Manual. NAG OxfordGoogle Scholar
- 13.Perry HM (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54: 58–72Google Scholar
- 14.Ramsay LE (1982) Hypertension. In: Wilkes E (ed) Long-term prescribing. Faber and Faber, London, pp. 18–38Google Scholar
- 15.McAreavey D, Ramsay LE, Latham L, Lorimer AR, McLaren D, Reid JL, Robertson JIS, Robertson MP, Weir RJ The “third drug” trial: a comparative study of antihypertensive agents added to treatment when blood pressure is uncontrolled by a beta-blocker plus thiazide diuretic. Br Med J (in press)Google Scholar